ArticleImmunity, inflammation and disease2025
Impact of Inactivated Influenza Vaccination on Health-Related Quality of Life Among Japanese Healthcare Workers.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and health-related quality of life following maternal respiratory syncytial virus (RSV) and diphtheria-tetanus-acellular pertussis (DTaP) vaccinations.Human vaccines & immunotherapeutics · 2026Article
- Impact of inactivated influenza vaccination on health-related quality of life for young children using Japanese experimental EuroQol toddler and infant populations (EQ-TIPS) v2.0.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfluenza vaccinations are recommended for healthcare workers (HCWs). Quantification of the personal risks of vaccination compared to vaccine benefits can help guide more accurate benefit-risk assessment and cost-effectiveness analysis of inactivated influenza vaccination among HCWs. The study objective was to evaluate the quality-adjusted life day (QALD) loss due to adverse events following immunization (AEFI) among HCWs.
methodsThis study used a questionnaire survey with the EuroQol-5 dimension-5 level (EQ-5D) for HCWs to evaluate the impact of reactogenicity on QALD loss following inactivated seasonal influenza vaccination. Participants were asked to answer a questionnaire survey regarding their health status once daily from the day before vaccination until 7 days after vaccination (a total of 9 times). QALD loss was calculated as the cumulative difference between the mean EQ-5D scores following vaccination (Days 0-7) and the mean EQ-5D score before vaccination (Day -1).
resultsDuring the study period, 213 participants completed the surveys for 5 days or more, and 122 participants completed the surveys for all days. The mean QALD losses among the participants who completed the surveys for five or more days and those who completed the surveys on all days were 0.040 and 0.054, respectively. The mean QALD losses among those by grade (the maximal grade of any AEFIs) were 0.021 (grade 0), -0.018 (grade 1), 0.089 (grade 2), and 0.299 (grade 3), respectively.
conclusionWe measured the magnitude of QALD loss in HCWs following inactivated influenza vaccination. These results support a more accurate health technology assessment of seasonal influenza vaccination in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.